This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Allergic Reaction to Depot Risperidone but Not to Oral Risperidone

Roy R. ReevesDO, PhD, and James E. Mack, PhD

Published: July 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Oral risperidone is an effective and well-tolerated atypicalantipsychotic1 that has been in widespread clinical usage forover 10 years. In recent years, a long-acting injectable form ofdepot risperidone with a delivery system different from otherdepot antipsychotics became available in the United Statesfollowing several years of marketing in other countries. Thisformulation consists of risperidone microencapsulated in 7525polylactide-co-glycolide (PLG) at a concentration of 381 mgof risperidone per gram of microspheres2; the PLG slowly hydrolyzesto release risperidone, allowing administration every2 weeks.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: Dementia , Neurologic and Neurocognitive


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...